➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,945,516

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,945,516
Title:Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Abstract: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
Inventor(s): Tamarkin; Dov (Ness Ziona, IL), Gazal; Elana (Rehovot, IL), Papiashvili; Irakliy (Askelon, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Moshav, IL), Keynan; Rita (Rehovot, IL)
Assignee: Foamix Pharmaceuticals Ltd. (Rehovot, IL)
Application Number:13/499,501
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,945,516

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Foamix AMZEEQ minocycline hydrochloride AEROSOL, FOAM;TOPICAL 212379-001 Oct 18, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Foamix ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,945,516

PCT Information
PCT FiledOctober 01, 2010PCT Application Number:PCT/IB2010/002612
PCT Publication Date:April 07, 2011PCT Publication Number: WO2011/039637

International Family Members for US Patent 8,945,516

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010302350   Start Trial
Australia 2015224534   Start Trial
Brazil 112012007473   Start Trial
Canada 2776366   Start Trial
Canada 2776471   Start Trial
Canada 2776474   Start Trial
Canada 2776482   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Merck
McKinsey
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.